Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Zolmitriptan
Aspen Pharma Pty Ltd
Medicine Registered
ZOLTRIP CMI 0812 ZOLTRIP _Zolmitriptan _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions people ask about ZOLTRIP. It does not contain all the information that is known about ZOLTRIP. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking ZOLTRIP against the benefits they expect it will have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT ZOLTRIP IS FOR ZOLTRIP belongs to a group of medicines called serotonin agonists. These medicines are used to relieve migraine. Migraine is thought to be caused by the widening of certain blood vessels in the brain. ZOLTRIP makes the blood vessels narrower to ease the migraine. Some people have a warning stage called 'aura' before the migraine headache starts. Aura can include numbness in the face or down one arm, changes in mood, or problems with eyesight such as seeing blank spots or flashing lights. ZOLTRIP can be used in migraine with or without aura. It should not be used to treat types of migraine called 'hemiplegic' or 'basilar' migraine. ZOLTRIP does not work in headaches that are not migraine. Your doctor will have explained why you are being treated with ZOLTRIP and told you what dose to take. FOLLOW ALL DIRECTIONS GIVEN TO YOU BY YOUR DOCTOR CAREFULLY. They may differ from the information contained in this leaflet. Your doctor may prescribe this medicine for another use. Ask your doctor if you want more information. ZOLTRIP is not addic Read the complete document
ZOLTRIP PRODUCT INFORMATION NAME OF THE MEDICINE Zolmitriptan. The chemical name is (_S_)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2- oxazolidinone. Its structural formula is: C 16 H 21 N 3 O 2 Molecular weight: 287.36 CAS No.: 139264-17-8 DESCRIPTION Zolmitriptan is a white to almost white powder slightly soluble in water (1.3 mg/mL at 250°C) but shows greater solubility in 0.1M hydrochloric acid. Zolmitriptan has a pKa of 9.6. Zolmitriptan is a chiral molecule, which is synthesised as the S enantiomer. ZOLTRIP tablets contain 2.5 mg of zolmitriptan. The tablets also contain microcrystalline cellulose, lactose, sodium starch glycollate type A, magnesium stearate and Opadry Pink 02G84574 (hypromellose, titanium dioxide, macrogol 400, macrogol 8000, iron oxide red). The tablets are gluten free. PHARMACOLOGY In pre-clinical studies, zolmitriptan has been demonstrated to be a selective agonist for the vascular human recombinant 5HT 1B and 5HT 1D receptor subtypes. Zolmitriptan is a high affinity 5HT 1B/1D receptor agonist with modest affinity for 5HT 1A receptors. Zolmitriptan has no significant affinity (as measured by radioligand binding assays) or pharmacological activity at 5HT 2 , 5HT 3 , 5HT 4 , α 1 , α 2 , or β 1 , adrenergic; H 1 , H 2 , histaminic; muscarinic; dopaminergic 1 , or dopaminergic 2 receptors. The N- desmethyl metabolite, 183C91, is also a 5HT 1B/1D agonist and is 2 to 6 times more potent, in animal models, than zolmitriptan. This metabolite shows higher in vitro affinity for 5HT 1B/1D receptors than zolmitriptan and also has modest affinity for 5HT 1A receptors. It has been demonstrated that the pain sensitive structures of the cranial cavity in humans are the blood vessels Read the complete document